M&AHealthcareSIGNED
Novo Nordisk Acquires Rights to Chinese Weight-Loss Drug for $2.6 Billion
Value
$2.6Bn
Acquirer
Novo Nordisk
Target
Hengrui Pharma's experimental weight-loss drug rights
Novo Nordisk has entered into a $2.6 billion deal to acquire the rights to an experimental weight-loss pill developed by Chinese pharmaceutical company Hengrui Pharma. The drug is designed for once-weekly administration.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.